|Podcasts|June 11, 2019
Episode 33: Translationally Enabled Pharma
Author(s)Lisa Henderson, Christen Harm
Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.
Advertisement
Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5